DUBLIN--(
BUSINESS WIRE
)--The
"New Drug Approvals and Their Contract Manufacture - 2023 Edition"
report has been added to
ResearchAndMarkets.com's
offering.
In 2022, the FDA approved c100+ new drug applications (NDAs) and biologics license applications (BLAs). This figure represents a decrease over the 2017-21 period. Both small molecule and biologic new molecular entity (NME) approvals declined substantially, causing overall NDA approvals to drop, which meant fewer commercial-scale production contracts for the most innovative products comparative to other recent years.
In June 2021, the FDA granted accelerated approval of Biogen's Aduhelm for Alzheimer's disease, despite there being little to no evidence of clinical benefit and the majority of an FDA advisory panel voting against the drug's approval. This event caused controversy and added to pre-existing claims that the FDA approval process may not be as rigorous as it was in the past, the long-standing push for speed in the FDA approval process having meant a reduced level of certainty and evidence related to a drug. As a result of these issues, there may have been an increased reluctance to authorize innovative drugs for use.
COVID-19 vaccine drives have allowed economies and societies to safely reopen during the pandemic. However, new challenges such as rising inflation will bring uncertainty to the ongoing global recovery. The pharma industry faces increasing cost pressures, shrinking consumer spending power, staff shortages, and geopolitical tensions. Contract Manufacturing Organization's (CMO's) will need to find ways to remain competitive in these difficult conditions while maintaining quality and compliance. High inflation will also impact supply chains and R&D activities, and challenge their feasibility.
New Drug Approvals and Their Contract Manufacture - 2023 Edition; is the 13th edition in the series of long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and their Contract Manufacture (formerly called 'CMO Scorecard') is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of Emergency Use Approvals for COVID-19 and how inflation has impacted pharma manufacturers.
Scope
This report gives important, expert insight you won't find in any other source. 11 tables and 34 figures throughout the report illustrate major points and trends.
This report is required reading for:
CMO executives who must have deep understanding of drug approvals and outsourcing to make strategic planning and investment decisions
Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management
Private equity investors that need a deeper understanding of the market to identify and value potential investment targets
Reasons to Buy
Overview of NDA drug and vaccine approvals and the levels of outsourcing associated with NDA sub segments
Detailed view of CDMO performance by number of drug and vaccine approvals
An assessment of pharmaceutical companies' propensity to outsource manufacture, by their market caps, based on the publisher's Contract Service Providers database
Outsourcing propensity for New Molecular Entities (NMEs), different dosage forms, and other drug attributes
Analysis of NME special product approvals such as those with Accelerated Approval, Orphan, Breakthrough or Fast Track designations and assessment of outsourcing
Key Topics Covered:
Executive Summary
Players
Technology Briefing
Innovative drug approvals
Dose outsourcing of drug approvals
Trends
Industry Analysis
Introduction
FDA NDA approvals overview
More biologic NME approvals than small molecule equivalents
Cell and gene therapies
First-in-class
First-time approvals
Rejected drugs
Predicted approvals for 2023
Sponsor trends
US vs. EU approval performance
FDA EUAs in 2022 for COVID-19
FDA: outsourced dose manufacture
Dosage form outsourcing
Special product categories
Accelerated approvals
Orphan drug designation
Fast track designation
Breakthrough therapy designation
Containment
Solubility enhancement
Outsourcing by company market cap
CMO performance
Dosage form
Outsourced API approvals
ANDA approvals
What it means
FDA approvals decline with a large decrease of NMEs approved
COVID-19 vaccine demand waning but there are still lucrative contracts
A few large CMOs gain majority of dose contracts
High inflation and other business conditions
Record high number of ATMP approvals in 2022
Value Chain
Companies
Appendix
Methodology
Bibliography
Primary research - key opinion leaders
Further reading
About the Authors
Contact the Publisher
Companies Mentioned
AbbVie Inc
ACS Dobfar SpA
Aenova Holding GmbH
Afton Scientific Corp
AGC Biologics Inc
Ajinomoto Bio-Pharma Services
Akorn Operating Company LLC
Alcami Corp
Alfasigma SpA
Allergopharma GmbH & Co KG
Almac Group Ltd
Alpex Pharma SA
Altasciences Co Inc
Alvogen Inc
AOP Health
ARx LLC
ASM Aerosol-Service AG
AstraZeneca Plc
Astrea SA
AtomVie Global Radiopharma Inc
Aurobindo Pharma Ltd
AustarPharma LLC
Avara Pharmaceutical Services Inc
Baccinex SA
Basic Pharma
Bausch & Lomb Pharmaceuticals Inc
Baxter Biopharma Solutions
Bayer AG
Berkshire Sterile Manufacturing LLC
BioRamo LLC
BioReliance Corp
Boehringer Ingelheim Biopharmaceuticals GmbH
Boehringer Ingelheim RCV GmbH & Co KG
Bora Pharmaceuticals Co Ltd
Bristol Myers Squibb Co
BSP Pharmaceuticals SpA
Bushu Pharmaceuticals Ltd
Cambrex Corp
Catalent Inc
Cenexi SAS
Cerovene Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Contract Pharmaceuticals Ltd
Corden Pharma International GmbH
CoreRx Inc
Corium Inc
Curia Global Inc
Delpharm SAS
Dexcel PT Israel Ltd
DPT Laboratories Ltd
Eisai Co Ltd
EMD Serono Inc
Emergent BioSolutions Inc
EuroAPI SAS
Eurofins Scientific SE
And Many More Companies!
For more information about this report visit
https://www.researchandmarkets.com/r/a0j1ls
Source: GlobalData
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.